^
AR positive
Salivary Gland Cancer
abiraterone acetate
Sensitive: C3 – Early Trials
J Clin Oncol - 2 weeks
No biomarker
Thyroid Gland Carcinoma
cabozantinib tablet
Sensitive: A1 - Approval
FDA - 4 weeks
FGFR1 rearrangement
Head and Neck Cancer
TAS 120
Sensitive: C3 – Early Trials
Cancer Discov - 4 weeks
FGFR1-PLAG1 fusion
Head and Neck Cancer
TAS 120
Sensitive: C4 – Case Studies
Cancer Discov - 4 weeks
No biomarker
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A1 - Approval
RET fusion
Thyroid Gland Carcinoma
pralsetinib
Sensitive: A1 - Approval
RET mutation
Thyroid Gland Medullary Carcinoma
selpercatinib
Sensitive: A1 - Approval
RET fusion
Thyroid Gland Carcinoma
selpercatinib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
sorafenib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Follicular Carcinoma
sorafenib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Papillary Carcinoma
sorafenib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Follicular Carcinoma
lenvatinib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
lenvatinib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Papillary Carcinoma
lenvatinib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Medullary Carcinoma
vandetanib
Sensitive: A1 - Approval
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib
Sensitive: A1 - Approval
RET mutation
Thyroid Gland Medullary Carcinoma
pralsetinib
Sensitive: A1 - Approval
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
dabrafenib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Carcinoma
lenvatinib
Sensitive: A1 - Approval
No biomarker
Head and Neck Cancer
cetuximab sarotalocan
Sensitive: A1 - Approval
No biomarker
Nasopharyngeal Carcinoma
toripalimab
Sensitive: A1 - Approval
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Medullary Carcinoma
dacarbazine
Sensitive: A2 - Guideline
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
TPF
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
pembrolizumab
Sensitive: A2 - Guideline
PD-L1 expression
Oral Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
cisplatin + paclitaxel + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
nivolumab
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
methotrexate
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
docetaxel
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
cisplatin + docetaxel
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
carboplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
cetuximab
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
capecitabine
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
afatinib
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
cisplatin
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
cisplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
cisplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
afatinib
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
capecitabine
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
methotrexate
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
docetaxel
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
carboplatin
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
cetuximab
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
carboplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
cisplatin + docetaxel
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
nivolumab
Sensitive: A2 - Guideline
PD-L1 expression
Oropharyngeal Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
cisplatin + paclitaxel + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
5-fluorouracil + hydroxyurea
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
carboplatin + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
5-fluorouracil + hydroxyurea
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
carboplatin + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
cisplatin
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
GC
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
carboplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Maxillary Sinus Carcinoma
VC
Sensitive: A2 - Guideline
No biomarker
Maxillary Sinus Carcinoma
EP
Sensitive: A2 - Guideline
No biomarker
Maxillary Sinus Carcinoma
CAV
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
DP
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
TPF
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Anaplastic Carcinoma
CaT
Sensitive: A2 - Guideline
MSI-H/dMMR
Maxillary Sinus Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
cetuximab
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
oxaliplatin
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
doxorubicin hydrochloride
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
ifosfamide
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
vinorelbine tartrate
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
irinotecan
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
capecitabine
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
docetaxel
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
nedaplatin
Sensitive: A2 - Guideline
No biomarker
Nasopharyngeal Carcinoma
cisplatin
Sensitive: A2 - Guideline
NTRK2 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: A2 - Guideline
TMB-H
Thyroid Gland Hurthle Cell Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
denosumab
Sensitive: A2 - Guideline
HER-2 positive
Salivary Gland Cancer
trastuzumab
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Follicular Carcinoma
denosumab
Sensitive: A2 - Guideline
TMB-H
Thyroid Gland Follicular Carcinoma
pembrolizumab
Sensitive: A2 - Guideline